The Exagamglogene autotemcel (Casgevy®) Pre-Infusion Supplemental Data Collection (2548) Form must be completed for recipients who are enrolled onto the CIBMTR study CS20-55. This is a post-marketing prospective, multicenter, observational, long-term registry-based study of recipients with transfusion-dependent β-thalassemia (TDT), or sickle cell disease (SCD) treated with exagamglogene autotemcel (exa-cel) (Casgevy®).
The Pre-Transplant Essential Data (Pre-TED) (2400) Form will confirm study eligibility; this includes event date and gene therapy product infused. Once eligibility is confirmed, the Exagamglogene autotemcel (Casgevy®) Pre-Infusion Supplemental Data (2548) Form will come due for all recipients along with the Recipient Baseline Data (2000) Form.
Links to sections of form:
Q1 – 19: Exagamglogene autotemcel
Manual Updates:
Sections of the Forms Instruction Manual are frequently updated. The most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.
To reference the historical Manual Change History for this form, review the retired manual section on the Retired Forms Manual webpage.
Section Updates:
| Date of Change | Manual Section | Add/Remove/Modify | Description |
|---|---|---|---|
| 1/23/2026 | 2548: Exagamglogene autotemcel (Casgevy®) Pre-Infusion | Add | Version 1 of the Exagamglogene autotemcel (Casgevy®) Pre-Infusion section of the Forms Instructions Manual released. Version 1 corresponds to revision 1 of the Form 2548. |
Need more help with this?
Don’t hesitate to contact us here.